| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| CMC/CMO(元) | - | - | 43,588,722.55 | 11,720,641.06 |
| 吡拉西坦注射剂(元) | - | - | 146,440,174.53 | 70,774,931.20 |
| 复方消化酶胶囊(元) | - | - | 207,037,184.61 | 97,311,962.65 |
| 甲钴胺片(元) | - | - | 52,280,623.10 | 25,149,494.95 |
| 注射用胰激肽原酶(元) | - | - | 39,379,380.50 | 17,934,690.24 |
| 奥曲肽注射剂(元) | - | - | 25,930,044.91 | - |
| CMC和CMO业务(元) | 54,556,282.31 | 18,893,754.99 | - | - |
| 抗肿瘤药及免疫调节剂(元) | 124,604,492.66 | 57,523,795.60 | - | - |
| 神经系统药物(元) | 179,959,744.20 | 95,147,720.99 | - | - |
| 消化道和代谢方面的药物(元) | 279,839,529.27 | 123,656,650.60 | - | - |
| 心血管系统药物(元) | 40,531,256.57 | 17,959,905.96 | - | - |
| 其他(元) | 42,504,565.95 | 17,877,633.77 | 92,718,295.19 | 44,987,246.71 |
| 营业成本(元) | ||||
| CMC/CMO(元) | - | - | 24,370,881.63 | 7,141,108.41 |
| 吡拉西坦注射剂(元) | - | - | 18,597,928.27 | 10,356,698.33 |
| 复方消化酶胶囊(元) | - | - | 53,424,858.62 | 25,411,365.73 |
| 甲钴胺片(元) | - | - | 19,334,797.78 | 10,007,160.41 |
| 注射用胰激肽原酶(元) | - | - | 3,861,718.08 | 1,887,097.31 |
| 奥曲肽注射剂(元) | - | - | 2,475,657.27 | - |
| CMC和CMO业务(元) | 33,338,848.57 | 12,448,545.20 | - | - |
| 抗肿瘤药及免疫调节剂(元) | 29,457,947.33 | 12,290,484.78 | - | - |
| 神经系统药物(元) | 31,242,494.02 | 16,207,911.25 | - | - |
| 消化道和代谢方面的药物(元) | 65,332,382.86 | 28,182,506.45 | - | - |
| 心血管系统药物(元) | 9,270,637.01 | 4,001,397.60 | - | - |
| 其他(元) | 18,151,026.26 | 7,240,000.11 | 29,139,747.85 | 11,884,150.43 |
| 毛利(元) | ||||
| CMC/CMO(元) | - | - | 19,217,840.92 | 4,579,532.65 |
| 吡拉西坦注射剂(元) | - | - | 127,842,246.26 | 60,418,232.87 |
| 复方消化酶胶囊(元) | - | - | 153,612,325.99 | 71,900,596.92 |
| 甲钴胺片(元) | - | - | 32,945,825.32 | 15,142,334.54 |
| 注射用胰激肽原酶(元) | - | - | 35,517,662.42 | 16,047,592.93 |
| 奥曲肽注射剂(元) | - | - | 23,454,387.64 | - |
| CMC和CMO业务(元) | 21,217,433.74 | 6,445,209.79 | - | - |
| 抗肿瘤药及免疫调节剂(元) | 95,146,545.33 | 45,233,310.82 | - | - |
| 神经系统药物(元) | 148,717,250.18 | 78,939,809.74 | - | - |
| 消化道和代谢方面的药物(元) | 214,507,146.41 | 95,474,144.15 | - | - |
| 心血管系统药物(元) | 31,260,619.56 | 13,958,508.36 | - | - |
| 其他(元) | 24,353,539.69 | 10,637,633.66 | 63,578,547.34 | 33,103,096.28 |
| 毛利率(%) | ||||
| CMC/CMO(%) | - | - | 44.09 | 39.07 |
| 吡拉西坦注射剂(%) | - | - | 87.30 | 85.37 |
| 复方消化酶胶囊(%) | - | - | 74.20 | 73.89 |
| 甲钴胺片(%) | - | - | 63.02 | 60.21 |
| 注射用胰激肽原酶(%) | - | - | 90.19 | 89.48 |
| 奥曲肽注射剂(%) | - | - | 90.45 | - |
| CMC和CMO业务(%) | 38.89 | 34.11 | - | - |
| 抗肿瘤药及免疫调节剂(%) | 76.36 | 78.63 | - | - |
| 神经系统药物(%) | 82.64 | 82.97 | - | - |
| 消化道和代谢方面的药物(%) | 76.65 | 77.21 | - | - |
| 心血管系统药物(%) | 77.13 | 77.72 | - | - |
| 其他(%) | 57.30 | 59.50 | 68.57 | 73.58 |
| 收入构成(%) | ||||
| CMC/CMO(%) | - | - | 7.18 | 4.38 |
| 吡拉西坦注射剂(%) | - | - | 24.11 | 26.42 |
| 复方消化酶胶囊(%) | - | - | 34.09 | 36.33 |
| 甲钴胺片(%) | - | - | 8.61 | 9.39 |
| 注射用胰激肽原酶(%) | - | - | 6.48 | 6.70 |
| 奥曲肽注射剂(%) | - | - | 4.27 | - |
| CMC和CMO业务(%) | 7.56 | 5.71 | - | - |
| 抗肿瘤药及免疫调节剂(%) | 17.26 | 17.38 | - | - |
| 神经系统药物(%) | 24.93 | 28.74 | - | - |
| 消化道和代谢方面的药物(%) | 38.76 | 37.35 | - | - |
| 心血管系统药物(%) | 5.61 | 5.42 | - | - |
| 其他(%) | 5.89 | 5.40 | 15.27 | 16.79 |
| 毛利构成(%) | ||||
| CMC/CMO(%) | - | - | 4.21 | 2.28 |
| 吡拉西坦注射剂(%) | - | - | 28.03 | 30.03 |
| 复方消化酶胶囊(%) | - | - | 33.67 | 35.74 |
| 甲钴胺片(%) | - | - | 7.22 | 7.53 |
| 注射用胰激肽原酶(%) | - | - | 7.79 | 7.98 |
| 奥曲肽注射剂(%) | - | - | 5.14 | - |
| CMC和CMO业务(%) | 3.96 | 2.57 | - | - |
| 抗肿瘤药及免疫调节剂(%) | 17.78 | 18.04 | - | - |
| 神经系统药物(%) | 27.79 | 31.49 | - | - |
| 消化道和代谢方面的药物(%) | 40.08 | 38.08 | - | - |
| 心血管系统药物(%) | 5.84 | 5.57 | - | - |
| 其他(%) | 4.55 | 4.24 | 13.94 | 16.45 |